Pain Therapeutics, Inc. (PTIE) Widens Q2 Loss to 7c/Share

Pain Therapeutics, Inc. (NASDAQ: PTIE) reported Q2 EPS of ($0.07), versus ($0.01) reported last year.

"In early 2014, we informed shareholders we would widen our pipeline of drug assets, while maintaining tight fiscal discipline," said Remi Barbier, Chairman, President & CEO. "At this mid-year mark, I'm pleased to report our strategy is moving along very well. We continue to believe Pfizer will file an NDA for REMOXY in 2015, we plan to initiate a clinical trial with a new abuse-resistant pain drug (hydromorphone) in the next quarter and we plan to disclose a novel pain product second half of 2014."

For earnings history and earnings-related data on Pain Therapeutics, Inc. (PTIE) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Northeast Community Bancorp, Inc. (NECB) Tops Q1 EPS by 12c
• Alphabet (GOOG) Tops Q1 EPS by 38c